Your browser doesn't support javascript.
Show: 20 | 50 | 100
Results 1 - 4 de 4
Filter
1.
Russian Cardiology Bulletin ; 15(3):64-71, 2020.
Article in Russian | Scopus | ID: covidwho-2322744

ABSTRACT

Patients with cardiovascular disease represent a particularly vulnerable population in a pandemic of the coronavirus infection COVID-19. They are more at risk of infection, a severe course of the disease, as well as a higher mortality rate compared to a healthy population. Currently, there are no randomized clinical trials to determine the most effective approaches to treatment in this category of patients. The presented clinical example demonstrates the possibilities of using various groups of drugs recommended for the treatment of COVID-19, and the high efficiency of treatment with an interleukin-6 receptor inhibitor (IL-6) in a patient with severe new coronavirus infection and the presence of concomitant cardiovascular pathology. © 2020, Media Sphera Publishing Group. All rights reserved.

2.
Messenger of Anesthesiology and Resuscitation ; 17(4):31-40, 2020.
Article in Russian | Scopus | ID: covidwho-1248503

ABSTRACT

The objective: To provide pathogenetic justification for the need for extracorporeal blood purification in the new coronavirus infection. Results: The article analyzes guidelines and the first experience of using extracorporeal methods in the new coronavirus infection in different countries. It has been demonstrated that methods of extracorporeal blood purification have complex pleiotropic (multiple) effects and can quickly normalize the level of cytokines and other pathogenic factors, thereby preventing/reducing the severity of organ disorders. The article specifies the criteria for choosing an extracorporeal method, as well as indications for its early and late use. © 2020 Messenger of Anesthesiology and Resuscitation. All rights reserved.

3.
Russian Electronic Journal of Radiology ; 10(3):20-25, 2020.
Article in Russian | Scopus | ID: covidwho-979847

ABSTRACT

urpose. To study the role of computed tomography (CT) in the diagnosis and evaluating of the dynamics in the course of viral pneumonia associated with COVID-19. Materials and methods. We demonstrate a clinical case of a 59-year-old patient who was diagnosed with viral pneumonia caused by a new coronavirus infection SARS-CoV-2. During the treatment, various methods of correction of the “cytokine storm” were used, including cytokine sorption and selective plasma filtration. To assess the dynamics of the course of the disease, CT data of the chest organs were used. Results. An analysis of a series of CT examinations together with monitoring changes in laboratory data made it possible to choose a therapy that helped to cure the patient. Conclusion. Computed tomography is an effective method for assessing the dynamics of viral pneumonia in COVID-19. © 2020 Russian Electronic Journal of Radiology. All rights reserved.

4.
Russian Cardiology Bulletin ; 15(3):64-71, 2020.
Article in English | Web of Science | ID: covidwho-940562

ABSTRACT

Patients with cardiovascular disease represent a particularly vulnerable population in a pandemic of the coronavirus infection COVID -19. They are more at risk of infection, a severe course of the disease, as well as a higher mortality rate compared to a healthy population. Currently, there are no randomized clinical trials to determine the most effective approaches to treatment in this category of patients. The presented clinical example demonstrates the possibilities of using various groups of drugs recommended for the treatment of COVID-19, and the high efficiency of treatment with an interleukin-6 receptor inhibitor (IL-6) in a patient with severe new coronavirus infection and the presence of concomitant cardiovascular pathology. Пациенты с наличием сердечно-сосудистых заболеваний (ССЗ) представляют особую уязвимую группу населения в условиях пандемии коронавирусной инфекции COVID -19. Они наиболее подвержены риску заражения, тяжелому течению заболевания, а также более высокой летальности по сравнению со здоровой популяцией. В настоящее время отсутствуют рандомизированные клинические исследования, позволяющие определить наиболее эффективные подходы к лечению у данной категории больных. Представленный клинический пример демонстрирует возможности применения различных групп препаратов, рекомендованных для лечения COVID-19 и высокую эффективность терапии ингибитором рецептора интерлейкина - 6 (ИЛ-6) у пациента с тяжелым течением новой коронавирусной инфекции и наличием сопутствующей сердечно-сосудистой патологии.

SELECTION OF CITATIONS
SEARCH DETAIL